Human Metabolome Technologies Inc (HMT) is a company that values innovation, scientific excellence, and collaboration. Their corporate philosophy revolves around advancing metabolomics research through cutting-edge technology, high-quality services, and strategic partnerships. HMT is committed to revolutionizing healthcare by understanding metabolic processes and developing targeted solutions for diagnosis, treatment, and drug development. By leveraging their expertise in metabolomics, HMT aims to provide valuable insights into human health and enable personalized medicine. Through their relentless pursuit of scientific discovery and commitment to societal well-being, Human Metabolome Technologies Inc stands as a leader in the field of metabolomics and aims to improve global health outcomes.

Human Metabolome Technologies Inc (HMT) is primarily present in Japan. As a leading metabolomics company, HMT is headquartered in Tsuruoka, Yamagata. With a strong focus on advancing metabolomics research and technology, HMT has established a significant presence in Japan. Through its innovative metabolomics solutions and services, HMT contributes to the advancement of bioinformatics and the understanding of human metabolism.

Some significant milestones achieved by Human Metabolome Technologies Inc include its establishment in 2003, becoming a publicly listed company in 2012, and partnering with various global pharmaceutical companies to advance metabolomics research. The company has consistently expanded its product portfolio, offering innovative solutions for metabolomics analysis. Human Metabolome Technologies Inc has also received several awards and recognitions for its contributions to the field of metabolomics, highlighting its expertise and leadership in this area. These milestones demonstrate the company's commitment to advancing metabolomics research and its significant impact on medical and scientific communities worldwide.

Human Metabolome Technologies Inc (HMT) is a prominent company specializing in metabolomics research and analysis. Founded in 2003, HMT has become a leader in the field, revolutionizing our understanding of metabolic profiling and its applications. The company provides state-of-the-art technology and advanced solutions to identify and quantify small molecule metabolites, aiding in the research of various diseases and drug development. HMT's groundbreaking research and collaborations have resulted in numerous patents and publications, establishing their credibility in the scientific community. Today, HMT continues to expand its capabilities and contribute to advancements in metabolomics research, making significant contributions to personalized medicine and beyond.

The main competitors of Human Metabolome Technologies Inc in the market include Metabolon Inc, Biocrates Life Sciences AG, and Metanomics Health GmbH.

Human Metabolome Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

Human Metabolome Technologies Inc (HMT) operates based on a unique business model in the field of metabolomics. HMT mainly focuses on metabolome analysis, which involves the comprehensive study of small molecules within biological systems. By employing advanced technologies and analytical methods, HMT offers services related to metabolomics research, including metabolome analysis, biomarker research, and personalized medicine development. As a leader in the field, Human Metabolome Technologies Inc aims to unlock valuable insights into metabolic profiles, leading to breakthrough discoveries in medicine, nutrition, and diagnostics.

De Human Metabolome Technologies K/W is 17,81.

De Human Metabolome Technologies KUV is 2,55.

De AlleAktien Kwaliteitsscore voor Human Metabolome Technologies is 5/10.

De verwachte Human Metabolome Technologies omzet is 1,41 mld. JPY.

De verwachte Human Metabolome Technologies winst is 202,54 mln. JPY.

The company Human Metabolome Technologies Inc (HMT) is a global leader in providing systems for the analysis of metabolites. HMT is headquartered in Japan and also operates branches in North America and Europe. The business model of HMT is to develop and offer innovative technologies for studying metabolic processes in biological systems. HMT focuses on three main areas: research and development, services, and products. The main goal of HMT is to enable a better understanding of metabolic processes in various biological systems, including human diseases. Research and Development HMT is a research company that focuses on the development of applications for analyzing human metabolism. The company utilizes state-of-the-art technologies and research findings to support the study of metabolic diseases, cancer, neurological disorders, and other medical conditions. HMT also engages in research collaborations with leading academic institutions and companies worldwide. Services The company also offers services to assist customers in the identification, quantification, characterization, and validation of metabolites in biological samples. HMT has developed a range of services that allow researchers and companies to investigate the metabolism of humans and animals in different states. HMT's services include: - Metabolome analysis - Bioinformatics analysis - Database services Metabolome analysis involves the quantitative analysis of metabolites in a biological sample. This analysis can be performed by HMT to investigate specific metabolic processes and identify disease-related changes. Bioinformatics analysis is the analysis of data from metabolome analyses. Mathematical algorithms are used to identify relationships between different metabolites and metabolic processes. Database services include access to HMT's metabolite-based databases, which provide access to metabolic pathway information, metabolic regulatory mechanisms, and disease-related metabolite profiles. Products HMT has developed a range of products that enable researchers and companies to investigate metabolic processes and perform metabolic analyses. HMT's product range includes: - LC-MS systems for metabolomic analysis of samples - Metabolite standards and reagents - Software and databases for the analysis of metabolic data HMT's LC-MS system is a powerful instrument for the quantitative analysis of metabolites in biological samples. The system is capable of identifying and quantifying hundreds of metabolites in a single sample. HMT's metabolite standards and reagents include a wide range of standard metabolites and isotopically labeled compounds. These products ensure precise and reliable analysis results. Conclusion HMT's business model encompasses research and development, services, and products that focus on the study of metabolites and metabolic processes in biological systems. HMT has established itself as a leading provider of metabolome analysis solutions and will continuously expand its product range to meet the needs of research institutions, pharmaceutical companies, biotechnology companies, and government agencies.

Human Metabolome Technologies keert een dividend van 0 JPY uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Human Metabolome Technologies of het bedrijf keert geen dividend uit.

De ISIN van Human Metabolome Technologies is JP3794530000.

De ticker van Human Metabolome Technologies is 6090.T.

Binnen de laatste 12 maanden betaalde Human Metabolome Technologies een dividend van 10,00 JPY . Dit komt overeen met een dividendrendement van ongeveer 1,64 %. Voor de komende 12 maanden zal Human Metabolome Technologies naar verwachting een dividend van 10,00 JPY betalen.

De dividendrendement van Human Metabolome Technologies is momenteel 1,64 %.

Human Metabolome Technologies betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Human Metabolome Technologies betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 10,00 JPY verwacht. Dit komt overeen met een dividendrendement van 1,64 %.

Human Metabolome Technologies wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Human Metabolome Technologies van 1-9-2024 ter hoogte van 15 JPY te ontvangen, moest je het aandeel voor de ex-datum op 27-6-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-9-2024.

In het jaar 2023 heeft Human Metabolome Technologies 0 JPY aan dividenden uitgekeerd.

De dividenden van Human Metabolome Technologies worden in JPY uitgekeerd.